FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer

Condition:   Colorectal Cancer Metastatic Intervention:   Drug: Oxaliplatin Sponsors:   Criterium, Inc.;   Amgen Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

A two ‐stage multicomponent parenchymal sparing surgical strategy (anatomical extended on left hepatic vein 2‐nd segment liver resection and R1vascular approach) allows the successful resection of synchronous multiple bilobar CRC metastases. AbstractA two ‐stage multicomponent parenchymal sparing surgical strategy (anatomical extended on left hepatic vein 2‐nd segment liver resection and R1vascular approach) allows the successful resection of synchronous multiple bilobar CRC metastases.
Source: Clinical Case Reports - Category: General Medicine Authors: Tags: CASE REPORT Source Type: research
In this study, we focused on the differential anti-cancerous effect of QC on two different human cancer cell lines, HCT 116 and INT 407. Results suggest that cytotoxicity increased in both the cell lines with an increase in QC concentration. The expression patterns of small-GTPases and caspases were altered significantly in QC-treated cells compared to non-treated cells. HSP70 and p53 showed comparable differences in the expression pattern. The wound-healing assay showed an increase in the denuded zone, with an increase in the concentration of QC. The formation of apoptotic nuclei increased with a rise in the concentration...
Source: Journal of Biosciences - Category: Biomedical Science Authors: Tags: J Biosci Source Type: research
ConclusionNEAT1 upregulateIGF2 expression through absorbing miR ‐185‐5p to enhances the migration and invasion of colon cancer cells.
Source: Molecular Genetics & Genomic Medicine - Category: Genetics & Stem Cells Authors: Tags: ORIGINAL ARTICLE Source Type: research
ConclusionIn summary, the above results indicate thatXIST promotes colorectal cancer tumorigenesis by regulating miR ‐93‐5p/HIF ‐1A/AXL signaling pathway, which will supply a novel perspective to diagnose and treat colorectal cancer disease.
Source: Molecular Genetics & Genomic Medicine - Category: Genetics & Stem Cells Authors: Tags: ORIGINAL ARTICLE Source Type: research
Conditions:   Colorectal Cancer;   Adenomatous Polyps;   Adenoma;   Advanced Adenoma Interventions:   Diagnostic Test: Multitarget stool FIT-DNA test - ColoClear;   Diagnostic Test: FIT;   Procedure: Colonoscopy Sponsors:   Zhejiang University;   New Horizon Health Technology Co., Ltd;   Beijing Mingze Technology Co., Ltd. Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Fear of Cancer Recurrence;   Colorectal Cancer;   Anxiety;   Health Anxiety;   Bodily Distress Syndrome Interventions:   Behavioral: TG-iConquerFear;   Behavioral: aTAU Sponsors:   Vejle Hospital;   Research Clinic for Functional Disorders, Aarhus University Hospital;   Centre for Oncology Education and Research Translation (CONCERT), Australia;   Danish Cancer Society Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
One kind of bacteria can cause colon tumours, while lacking another kind of microbe may lead to ulcerative colitis, an inflammatory bowel condition
Source: New Scientist - Health - Category: Consumer Health News Source Type: research
(Hubrecht Institute) Cancer mutations can be caused by common gut bacteria. By exposing human mini-guts to a particular strain of Escherichia coli, scientist uncovered that these bacteria induce a unique mutational pattern in human DNA. This pattern was also found in colon cancer patients, implying that the bacteria induced these mutations. For the first time the researchers establish a direct link between microbes and mutations driving tumorigenesis. This might lead to new measures in colorectal cancer prevention.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
(University of Texas M. D. Anderson Cancer Center) Combined therapy may improve clinical responses for endometrial, colorectal and gastric tumors. Enzyme inhibitor with anti-PD1 checkpoint blockade boosted efficacy over either treatment alone.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Publication date: May 2020Source: Biomedicine &Pharmacotherapy, Volume 125Author(s): Wen Dacheng, Li Songhe, Jiang Weidong, Zhao Shutao, Liu Jingjing, Zhu Jiaming
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Colorectal Cancer | Eloxatin | Research